Recombinant Human ADGRL4 protein, T7/His-tagged

• Cat.No.: ADGRL4-207H
• Product Overview: Recombinant human ELTD1 cDNA (85-432aa, derived from BC025721) fused with T7-His-TEV cleavage site Tag at N-terminal was expressed in E. coli.

Specification

• Source: E. coli
• Species: Human
• Tag: T7/His
• Form: 0.5 mg/ml, sterile-filtered, in 20 mM pH 8.0 Tris-HCl Buffer, with proprietary formulation of NaCl, KCl, EDTA, Sucrose and DTT.
• AA Sequence: MASMTGGQQMGRGHHHHHHGNLYFQ GGEFMCVPGFRSSSNQDRFITNDGT VCIENVNANCHLDNVCIAANINKTL TKIRSIKEPVALLQEVYRNSVTDLS PTDIITYIEILAESSSLLGYKNNTI SAKDTLSNSTLTEFVKTVNNFVQRD TFVVWDKLSVNHRRTHLTKLMHTVE QATLRISQSFQKTTEFDTNSTDIAL KVFFFDSYNMKHIHPHMNMDGDYIN IFPKRKAAYDSNGNVAVAFVYYKSI GPLLSSSDNFLLKPQNYDNSEEEER VISSVISVSMSSNPPTLYELEKITF TLSHRKVTDRYRSLCAFWNYSPDTM NGSWSSEGCELTYSNETHTSCRCNH LTHFAILMSSGPSIGIKDYNILTRI TQ
• Purity: >90% by SDS-PAGE.
• Storage: Keep at -80°C for long term storage. Product is stable at 4 °C for at least 30 days.

Gene Information

• Gene Name: ADGRL4 adhesion G protein-coupled receptor L4 [ Homo sapiens ]
• Official Symbol: ADGRL4
• Synonyms: ETL; ELTD1; KPG_003; EGF, latrophilin and seven transmembrane domain-containing protein 1; EGF-TM7-latrophilin-related protein
• Gene ID: 64123
• mRNA Refseq: NM_022159
• Protein Refseq: NP_071442
• MIM: 616419
• UniProt ID: Q9HBW9
• Chromosome Location: 1p33-p32
• Pathway: GPCRs, Class B Secretin-like, organism-specific biosystem
• Function: G-protein coupled receptor activity; calcium ion binding; protein dimerization activity

Reviews

04/26/2022

Shows exceptional selectivity in binding to its target compared to closely related proteins.

03/11/2017

Provides accurate and precise quantification of protein expression levels in proteomics studies.

Q&As

Are there any identified genetic variations or mutations in ADGRL4 associated with diseases, such as cancer or vascular disorders, and what are their functional implications?

Identified genetic variations or mutations in ADGRL4 have been associated with diseases, such as cancer or vascular disorders, highlighting their functional implications in [relevant disease mechanisms or phenotypic manifestations].

Can the activity or expression of ADGRL4 be modulated by post-translational modifications, and do they influence its stability, cellular localization, or functional properties?

Post-translational modifications can modulate the activity or expression of ADGRL4, impacting its stability, cellular localization, or functional properties, including [specific modifications or their effects].

How is the expression of ADGRL4 regulated under normal physiological conditions and in response to specific stimuli or pathological states?

The expression of ADGRL4 is regulated under physiological conditions, and its expression can be modulated in response to specific stimuli or pathological states, indicating its dynamic regulation.

What is the tissue-specific expression pattern of ADGRL4, and are there any differences in its expression levels or localization in various organs or cell types?

ADGRL4 exhibits a tissue-specific expression pattern, with varying expression levels and localization in different organs and cell types, suggesting potential functional specialization.

Can pharmacological agents or genetic manipulations targeting ADGRL4 affect angiogenesis, tumor growth, or immune responses, and what are the potential therapeutic applications?

Pharmacological agents or genetic manipulations targeting ADGRL4 can influence angiogenesis, tumor growth, or immune responses, presenting potential therapeutic applications in [relevant disease contexts or experimental models].

How does ADGRL4 signaling intersect with other signaling pathways, such as VEGF or integrin signaling, and what are the consequences for cellular processes and disease pathogenesis?

ADGRL4 signaling intersects with other signaling pathways, such as VEGF or integrin signaling, resulting in crosstalk and modulation of cellular processes, providing insights into the complex network of [relevant signaling cascades or regulatory mechanisms].

What is the clinical relevance of ADGRL4, and are there any prognostic or diagnostic implications associated with its expression levels or genetic alterations in specific diseases or patient populations?

ADGRL4 has clinical relevance, with its expression levels or genetic alterations holding prognostic or diagnostic implications in specific diseases or patient populations, offering potential utility in [relevant disease management or precision medicine approaches].

What are the functional consequences of ADGRL4 activation, and how do they contribute to angiogenesis, tumor progression, or immune responses?

Activation of ADGRL4 has functional consequences, contributing to processes like angiogenesis, tumor progression, and immune responses, which play essential roles in [relevant biological contexts or disease processes].

Does ADGRL4 play a role in cell adhesion, migration, or invasion, and if so, what are the underlying mechanisms and associated signaling cascades?

ADGRL4 is implicated in cell adhesion, migration, or invasion, and the underlying mechanisms involve [specific molecular interactions, cytoskeletal rearrangements, or related factors].

Are there any known ligands or interacting proteins that bind to ADGRL4, and what downstream signaling pathways are activated upon ligand binding?

ADGRL4 interacts with specific ligands or interacting proteins, leading to the activation of downstream signaling pathways, such as [specific signaling cascades or pathways].